Six-month results from a Phase III randomized trial of fixed-combination brinzolamide 1% + brimonidine 0.2% versus brinzolamide or brimonidine monotherapy in glaucoma or ocular hypertension.

A slight trend towards a decrease in blood pressure was observed from the baseline visit to the six-month visit for patients in the BBFC group (3.3–4.2 mmHg decrease) and the brimonidine group (2.9–5.0 mmHg decrease), but the scatter plots in Figure 2 show that blood pressure in individual patients remained relatively stable from baseline to six months, regardless of the study medication used.

also in 4,078 other papers